Allergic Disorder Clinical Trial
Official title:
A Phase 1, Open-Label, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ASLAN004 in Healthy Subjects
This is an open-label, two-part, single-center, first in human (FIH), single ascending dose (SAD) study to assess the effects of single doses of ASLAN004 when administered to healthy subjects. The objective of this study is to evaluate the safety, tolerability, and Pharmacokinetics (PK) of ASLAN004 in healthy subjects.
The plan is to enroll between 38 to 50 subjects at 1 study center.
The study is divided into 2 parts:
Part A is designed as a SAD study using intravenous (IV) administration of ASLAN004, as a
single mg/kg IV dose and will consist of up to 6 IV cohorts.
Part B is designed as a parallel SAD study using subcutaneous (SC) administration of
ASLAN004, as a single fixed milligram SC dose and will consist of up to 4 SC cohorts.
All cohorts will have sentinel dosing with the first subject of each cohort being spaced with
adequate observation time of 24 to 48 hours before dosing the remaining subjects in the
cohort.
All subjects would be follow up for up to 85 days from the last dosing day.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03922087 -
No-worry Baby Project
|
||
Recruiting |
NCT04189978 -
Impact of Microbial Exposure of the Habitat at the Time of Birth on the Development of Allergic Diseases.
|
||
Completed |
NCT03344783 -
The Effects of Early Life PUFA and R-TFA on AD: A Systematic Review and Meta-analysis
|
N/A | |
Completed |
NCT05442658 -
Importance and Association of Gut Microbiota and Biochemical Metabolites on Children Allergic Disorder
|